Plant will enable Mapi to supply the initial commercial needs of GA Depot NESS ZIONA, Israel – March 18, 2019 – Mapi Pharma Ltd., a fully integrated, clinical, late stage biopharmaceutical company, announced today that it has received complementary funding from the...
Analyst Lunch and Live Webcast on Tuesday March 5th at 12 Noon ET NESS ZIONA, Israel – February 21, 2019 – Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) luncheon on its...
NESS ZIONA, Israel, November 5th, 2018. Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an equity investment of $10 million by Zhejiang Jingxin Pharmaceutical Co., Ltd. a publicly listed Chinese...
81.8% Patients on GA Depot Demonstrated No Evidence of Disease Activity (NEDA) at 2 years GA Depot Has Potential to Address Multiple Sclerosis Treatment Burden and Improve Patient Compliance NESS ZIONA, Israel – Oct. 9th, 2018 – Mapi Pharma Ltd., a fully integrated,...
Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis Mapi Pharma has completed an open-label Phase II clinical trial and is preparing to commence a pivotal Phase III clinical trial to support...
NESS ZIONA, Israel – February 6, 2018 – Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) luncheon on its GA Depot, a novel long-acting depot formulation of glatiramer... 